FDA-cleared profile

Annalise Enterprise CXR Triage Trauma

Annalise-AI Pty Ltd · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Triage and prioritization of adult chest X-ray cases suggestive of pleural effusion or pneumoperitoneum.

Clinical role
Analyzes adult chest X-rays for features suggestive of pleural effusion and pneumoperitoneum and makes case-level output available to PACS or RIS for worklist prioritization, in parallel to standard interpretation; it never decreases a study's existing priority.
Images and patients
X-ray/Radiography · Chest
Key limitation
Keep in mind: Not standalone and not a rule-out device; only pleural effusion and pneumoperitoneum are identified; prone positioning, unilateral left-sided pneumoperitoneum, scarring, and pleural thickening may affect performance.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Triage and prioritization of adult chest X-ray cases suggestive of pleural effusion or pneumoperitoneum.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest Input: Adult DICOM-compliant chest X-ray studies obtained through image and order management systems; evaluation included supine and erect positioning.
  • Who uses it?Intended users: Trained clinicians qualified to interpret chest X-rays.
  • What does the software produce?Output: Case-level notification to PACS or RIS for worklist prioritization or triage; existing study priority is not lowered and no image location is marked.
  • What is its most important limitation?Key limitation: Not standalone and not a rule-out device; only pleural effusion and pneumoperitoneum are identified; prone positioning, unilateral left-sided pneumoperitoneum, scarring, and pleural thickening may affect performance.

Clinical takeaway. Clinical role: Triage and prioritization of adult chest X-ray cases suggestive of pleural effusion or pneumoperitoneum.

Evidence takeaway. Evidence from the reviewed source record: FDA packet reports two retrospective cohorts totaling 1,269 adult DICOM CXR cases, 582 positive and 687 negative, from four US hospital-network sites; AUC was 0.980 for pleural effusion and 0.969 for pneumoperitoneum.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Triage and prioritization of adult chest X-ray cases suggestive of pleural effusion or pneumoperitoneum.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Analyzes adult chest X-rays for features suggestive of pleural effusion and pneumoperitoneum and makes case-level output available to PACS or RIS for worklist prioritization, in parallel to standard interpretation; it never decreases a study's existing priority.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "adult chest X-ray cases with features suggestive of pleural effusion and pneumoperitoneum in the medical care environment. The device analyzes cases using an artificial intelligence algorithm to identify findings. It makes case-level output available to a PACS or RIS for worklist prioritization or triage." … "It is important to note that the device will never decrease a study’s existing priority in the worklist.". Read from the exact FDA decision document on 2026-11-14.

Required input
Adult DICOM-compliant chest X-ray studies obtained through image and order management systems; evaluation included supine and erect positioning.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
Case-level notification to PACS or RIS for worklist prioritization or triage; existing study priority is not lowered and no image location is marked.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Trained clinicians qualified to interpret chest X-rays.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
Not standalone and not a rule-out device; only pleural effusion and pneumoperitoneum are identified; prone positioning, unilateral left-sided pneumoperitoneum, scarring, and pleural thickening may affect performance.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
FDA packet reports two retrospective cohorts totaling 1,269 adult DICOM CXR cases, 582 positive and 687 negative, from four US hospital-network sites; AUC was 0.980 for pleural effusion and 0.969 for pneumoperitoneum.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA packet reports two retrospective cohorts totaling 1,269 adult DICOM CXR cases, 582 positive and 687 negative, from four US hospital-network sites; AUC was 0.980 for pleural effusion and 0.969 for pneumoperitoneum.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Reported sensitivity
Pneumoperitoneum: 82.2% (95% CI: 75.2%, 89.1%) Pleural Effusion: 93.8% (95% CI: 91.5%, 95.8%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
Pneumoperitoneum: 96.2% (95% CI: 93.4%, 98.9%) Pleural Effusion: 91.7% (95% CI: 89.3%, 94.1%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Annalise CXR - Pneumoperitoneum / Pleural Effusion regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested version3.3+
  • IndependenceIndependence not established

K222179

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K222179. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult DICOM-compliant chest X-ray studies obtained through image and order management systems; evaluation included supine and erect positioning.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K222179: Annalise Enterprise CXR Triage Trauma

  2. Routing

    Source context, not route validation: The exact FDA package describes the device interfacing with image and order management systems (such as PACS/RIS) to obtain chest X-ray studies, providing notifications to that system, and making case-level output available to a PACS or RIS for worklist prioritization or triage. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "The device interfaces with image and order management systems (such as PACS/RIS) to obtain CXR studies for processing by the AI algorithm." … "the device provides a notification to the image and order management system for prioritization of that study in the worklist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA K222179: Annalise Enterprise CXR Triage Trauma

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: Case-level notification to PACS or RIS for worklist prioritization or triage; existing study priority is not lowered and no image location is marked.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K222179: Annalise Enterprise CXR Triage Trauma

  5. Viewer/worklist/report

    Unresolved route: Case-level notification to PACS or RIS for worklist prioritization or triage; existing study priority is not lowered and no image location is marked.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K222179: Annalise Enterprise CXR Triage Trauma

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The exact FDA package describes the device interfacing with image and order management systems (such as PACS/RIS) to obtain chest X-ray studies, providing notifications to that system, and making case-level output available to a PACS or RIS for worklist prioritization or triage. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The device interfaces with image and order management systems (such as PACS/RIS) to obtain CXR studies for processing by the AI algorithm." … "the device provides a notification to the image and order management system for prioritization of that study in the worklist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Harrison.ai's Data Privacy FAQs (issued 2025-09-25) state a compliance baseline aligned with the GDPR and the Australian Privacy Act; that medical image data processed by its solutions is encrypted and pseudonymised or de-identified with measures to minimise re-identification risk; that customer patient images are not collected to train AI models; and that technical, organisational and administrative safeguards protect personal data. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the FDA applicant is Annalise-AI Pty Ltd; Harrison.ai's own Annalise Enterprise page (2023-08-09, harrison.ai/annalise-enterprise/) states Annalise.ai is now Harrison-AI Medical Pty Ltd, an entity the Harrison.ai privacy notice lists in Section 14, and annalise.ai/privacy-policy redirects to that notice. The FAQ names Harrison.ai. Company-level statement; exact-release scope is not established.

Supported acquisition environment

Supported hardware: Unspecified. Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Annalise Enterprise CXR Triage Trauma; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K222179
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Chest
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-03-28
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K222179 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K222179: Annalise Enterprise CXR Triage Trauma

    U.S. Food and Drug Administration - Published 2023-03-28 - Accessed 2026-09-19

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, integration

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Annalise CXR - Pneumoperitoneum / Pleural Effusion model card (K222179)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K222179

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. Harrison.ai: Data Privacy FAQs

    Harrison.ai - Published 2025-09-25 - Accessed 2026-10-26

    Scope: security

Research history

  1. K222179 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K211803

HealthPPT

Zebra Medical Vision Ltd.

Authorized purpose: Aid assessment and triage of adult frontal chest X-rays with suspected pneumoperitoneum.

Modality
X-ray/Radiography
Anatomy
Chest
Decision
2021-12-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history